MRVI

• Net loss for Q2 2026 was $(21.6) million, compared to a net loss of $(69.8) million in Q2 2025.
• Adjusted EBITDA for Q2 2026 was $8.7 million, compared to $(10.4) million in Q2 2025.
• TriLink revenue increased 11.5% year-over-year, while Cygnus revenue increased 2.8%.
• Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; revenue guidance reiterated at $205 million to $215 million.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The new credit agreement provides a $150.0 million term loan facility and a $30.0 million revolving credit facility, both maturing June 2, 2032.
• Proceeds from the new term loan plus approximately $98.5 million cash on hand were used to prepay in full and terminate the prior credit agreement dated October 19, 2020.
• The refinancing reduces aggregate outstanding principal from approximately $242.9 million to $150.0 million.
• Borrowings bear interest at Term SOFR plus 5.00% per annum, with a 0.25% stepdown if the consolidated first lien net leverage ratio is 3.00 to 1.00 or less.

1.01 Entry into a Material Definitive Agreement · 1.02 Termination of a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 was ratified with 234,492,897 votes for, 1,246,939 against, and 343,132 abstentions.
• Shareholders approved, on a non-binding advisory basis, the compensation of named executive officers with 200,054,156 votes for, 2,457,403 against, and 312,439 abstentions.
• A quorum was present with 236,082,968 shares of common stock represented, out of 258,180,170 shares outstanding as of the March 27, 2026 record date.
• The report was filed under Item 5.07 to disclose the final voting results of the matters submitted to a shareholder vote.

5.07 Submission of Matters to a Vote of Security Holders

• First quarter 2026 total revenue was $65.8 million, a 40.5% increase from $46.9 million in the prior year period.
• TriLink segment revenue grew 65.1% to $47.5 million, driven by $14.3 million of high-volume CleanCap orders for COVID vaccines; base revenue excluding COVID CleanCap grew 15.4%.
• Cygnus segment revenue increased 1.4% to $18.4 million, with strength in North America and EMEA partially offset by China distributor timing.
• The company raised full-year 2026 revenue guidance to $205-$215 million and Adjusted EBITDA guidance to $30-$32 million.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Full year 2025 revenue was $185.7 million, down 28.3% year-over-year, with net loss of $(230.8) million and Adjusted EBITDA of $(31.2) million.
• Company introduces full year 2026 revenue guidance of $200 million to $210 million and Adjusted EBITDA guidance of $18 million to $20 million.
• TriLink segment revenue decreased 17.4% in Q4 and 39.0% for the full year, primarily due to lack of high-volume CleanCap orders; Cygnus segment revenue increased 4.1% in Q4 and 5.0% for the full year.
• Reporting segment names updated: Nucleic Acid Production to TriLink and Biologic Safety Testing to Cygnus, with no impact on financial results.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Third quarter 2025 revenue was $41.6 million, down 39.7% year-over-year from $69.0 million.
• Net loss for Q3 2025 was $45.1 million, compared to a net loss of $172.5 million in Q3 2024.
• Nucleic Acid Production revenue fell 52.9% to $25.4 million, while Biologics Safety Testing rose 7.2% to $16.3 million.
• Full-year 2025 revenue guidance is approximately $185.0 million, excluding high-volume CleanCap orders and potential acquisitions.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• The resignations were part of efforts to rationalize board size and reduce administrative costs, and were not due to any disagreement with management or the Board.
• The Board reduced its size from eleven to eight directors, effective October 27, 2025.
• Following the resignations, R. Andrew Eckert was appointed chair of the Nominating, Governance and Risk Committee and a member of the Audit Committee; Gregory T. Lucier was appointed to the Nominating, Governance and Risk Committee.
• The Board accelerated vesting of all unvested restricted stock unit awards held by the departing directors, effective as of the resignation date.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

• Buzzeo's last day is expected to be September 2, 2025; Leddy's last day is expected to be October 2, 2025.
• Both departures are terminations without 'cause' under their Amended and Restated Employment Agreements dated May 8, 2023.
• Each will receive payments and benefits per Section 1(f)(i) of their agreements, subject to signing a separation agreement and release of claims.
• The severance costs are included in the estimated $8.0–$9.0 million restructuring costs disclosed in Item 2.05.

2.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits